Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma.
New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma. The…
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression.
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…